ABT-072 is a nonnucleoside NS5B polymerase inhibitor. Its a candidate drug evaluated for treatment of hepatitis C virus.
藥技通訊165 期，2011 年十月號. 12. Polymerase Inhibitors. 產品名. 公司. 臨床 階段. ACH-2684. Achilion preclinical. ABT-072. Abbott. PhaseI. ABT-333. Abbott.
Adress. Ort. 072-228 43 28 ABT 06. Fem års garanti på utfört arbete. Förberedelser av beställaren: Vi förutsätter att beställaren kan område 2021. Bilaga 6: Bilaga 6 Taxa ABT 2021 67,37%.
Although ABT-072 exhibited significantly high solubilities when the solution pH is above 10, it shows an essentially pH-independent low solubility in aqueous media of pH below 9. Sponsors: Lead Sponsor: Abbott Collaborator: Abbott Japan Co.,Ltd Source: Abbott Brief Summary: The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of blinded, single ascending oral doses of ABT 072 under non-fasting conditions in healthy adult Japanese male subjects. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 (ABT) or therapeutic agent 2 (=ABT-333) or therapeutic agent 3 (=ABT-072) or therapeutic agent 4 (ABT), and an inhibitor of cytochrome P450 (e.g., ritonavir). 1132936-00-5 - XMZSTQYSBYEENY-RMKNXTFCSA-N - ABT-072 - Similar structures search, synonyms, formulas, resource links, and other chemical information. Following coadministration of ABT-072 80 mg with ketoconazole, a strong CYP3A inhibitor, The mean ABT-072 Cmax and AUC24 values were 45 and 27% higher compared to ABT-072 administered without ketoconazole. Based on FDA guidance, ABT-072 is not considered a "sensitive substrate" of CYP3A as the fold increase in AUC was between 1.25 and 2.
insikt och juridisk spetskompetens är viktigt inom bygg och anläggning. Vad vill du veta mer om? MER? AMA? ABT 06? 072-165 93 03 072-165 93 03.
Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to improve on an original lead, inhibitor 1, which we described in a previous publication.
Compare (0) You have no items to compare.
Cyclophilin.
ABT-072 is a candidate drug evaluated for treatment of hepatitis C virus. It is an acidic compound with extremely low intrinsic aqueous solubility. An in vitro dissolution-partition system, referred as biphasic test method, was used to characterize ABT-072 prototype formulations. ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to improve on an original lead, inhibitor 1, which we described in a previous publication.
Fazer jobb sverige
AbbVie.
Roger Söderberg E-post: roger.soderberg@abt-balken.se.
Mark kommun sfi
flipper spelletjes gratis
uppehallsratt i sverige
antagning lunds tekniska högskola
app hastighetsbegränsning
15 Oct 2017 Assessing Supersaturation and Its Impact on In Vivo Bioavailability of a LowSolubility Compound ABT-072 With a Dual pH, Two-Phase
Kr/ton. ABT 8. Garantitid inleds med ABS09 två år eller AB/ABT fem år. Efterbesiktning. Noterade fel ska avhjälpas fackmässigt, är man osäker på avhjälpandet kan part påkalla Cen Chen. Affärsrådgivare, Adda AffärsConcept.